Skip to main content
Fig. 2 | European Journal of Medical Research

Fig. 2

From: B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia

Fig. 2

Structure and functional verification of B7-H3-CAR. A Schematic diagram of B7-H3-CAR, including the EF1 promoter, B7-H3 single-chain antibody, CD8 transmembrane structure, co-stimulation domain 41-BB, and intracellular signal domain CD3Z. B Flow cytometry analysis of B7-H3-CAR expression on the surface of Jurkat cells after transduction. C Expression of CD25 and CD69 on the surface of Jurkat and B7-H3-CAR-Jurkat cells was detected by flow cytometry using CD25-APC and CD69-APC antibodies after 48 h of 1:1 co-incubation with HEL, AML5 and KG-1 cells, respectively (n = 3 wells/group). In the figure, +++, ++ and + represent the high, medium and low expression of B7-H3 in cells, respectively. D The secretion of IL-2, TNF, INF-γ and granzyme B cytokines in the supernatant after the above co-incubation was measured

Back to article page